Roth Capital Predicts Reduced Earnings for Gain Therapeutics

Gain Therapeutics, Inc. (NASDAQ:GANX) – Stock analysts at Roth Capital lowered their Q2 2025 earnings per share (EPS) estimates for Gain Therapeutics in a research note issued to investors on Wednesday, May 14th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings per share of ($0.18) for the quarter, down from their prior estimate of ($0.17). The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics’ Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.71) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($0.84) EPS.

Several other analysts have also issued reports on GANX. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a research note on Monday, March 17th. Chardan Capital restated a “buy” rating and issued a $6.00 target price on shares of Gain Therapeutics in a research note on Friday, March 28th. Finally, Scotiabank began coverage on Gain Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price target for the company. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $8.20.

Gain Therapeutics Stock Performance

Shares of Gain Therapeutics stock opened at $2.01 on Monday. The business’s fifty day simple moving average is $1.94 and its 200 day simple moving average is $2.01. The firm has a market capitalization of $59.15 million, a P/E ratio of -1.83 and a beta of 0.17. Gain Therapeutics has a 12 month low of $0.89 and a 12 month high of $3.19. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.16) EPS for the quarter, hitting analysts’ consensus estimates of ($0.16).

Hedge Funds Weigh In On Gain Therapeutics

Several hedge funds have recently made changes to their positions in GANX. Sprott Inc. purchased a new position in shares of Gain Therapeutics in the fourth quarter valued at $30,000. Benedict Financial Advisors Inc. purchased a new position in Gain Therapeutics during the fourth quarter worth about $35,000. Bridgeway Capital Management LLC purchased a new position in Gain Therapeutics during the fourth quarter worth about $65,000. Kovitz Investment Group Partners LLC purchased a new position in Gain Therapeutics during the first quarter worth about $91,000. Finally, Northern Trust Corp grew its position in Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after buying an additional 39,642 shares in the last quarter. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.